Ths object of this study was to examine validity, meaningful effect sizes, and patterns of response of the Transition @entity1353 Index (TDI) in a clinical trial cohort of @entity1030 ( @entity1030 ) @entity1 . The design was a retrospective analysis of data from a randomized, double-blind placebo-controlled clinical trial. We analyzed fifty clinical investigation sites in United States. There were 921 @entity1 with stable @entity1030 . @entity5489 18 microg dry powder or matching placebo was used. @entity1 were allowed to remain on usual care less @entity13265 . Construct validity was demonstrated by significant correlations (P <.05) between Baseline @entity1353 Index (BDI) and other baseline measures, as well as between TDI and changes in other measures at the end of 1 year. Concurrent validity was observed by the significant correlation between TDI and @entity1353 diary responses. Changes in TDI focal score were in the range of one unit when the group was stratified by a minimal change in the physician's global evaluation. Significantly less (P <.05) supplemental @entity3045 was observed in the group of responders defined by a one-unit improvement in TDI. Responders also had few exacerbations and better health status. The validity of the TDI is supported in a large clinical trial setting. A one-unit change in the TDI focal score represented the minimal important difference.

Meaningful effect size and patterns of response of the transition XXXX index.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity5489 :: ('MESH:C079890', 'Chemical') :: ['Tiotropium'] @entity13265 :: ('MESH:D009241', 'Chemical') :: ['ipratropium bromide'] @entity1353 :: ('MESH:D004417', 'Disease') :: ['Dyspnea', 'dyspnea'] @entity3045 :: ('MESH:D000420', 'Chemical') :: ['albuterol'] @entity1030 :: ('MESH:D029424', 'Disease') :: ['chronic obstructive pulmonary disease', 'COPD']
@entity1353 :: (MESH:D004417,Disease) :: ['dyspnea']
